US-based biotech firm to hire more Filipino engineers as part of PH expansion

US-based InterVenn Biosciences (Intervenn) is set to open a new and bigger office in Ortigas as part of its expansion efforts. It is also looking to hire up to 100 employees, including developers and engineers who will form the backbone of its proprietary artificial intelligence (AI) technology used in the company’s research.

InterVenn is a medical company focused on glycoproteomic research and development, and employs a proprietary platform powered by AI and mass spectrometry to help advance oncology and other related fields. It is based in San Francisco, California,

Schedule to open in January 2022, the new site will integrate its different teams from product management to marketing and web development in an open office format. The new InterVenn office intends to promote collaboration, boost productivity, and raise the bar of skills and competence in IT engineering.

Biotech firm InterVenn Biosciences raises P10 billion for cancer research
SAS updates life science analytics to improve drug and vaccine development

“One hundred percent of our software is done in the Philippines,” said Aldo Carrascoso, founder and CEO of Intervenn. “Our engineering team in our Mandaluyong City office takes care of the cloud infrastructure, front end, back end, and even security. Information security, information event management, events like infiltration, penetration testing. We have a full staff that does dev ops, server systems administration.”

Carrascoso hails from the Philippines.

Recently, InterVenn completed a P10 billion Series C financing led by SoftBank Group, one of the biggest investors in the world. The funding is now being used for its aggressive recruitment and expansion, and to support the development and commercialization of Dawn, a blood-based test aimed at helping physicians appropriately match cancer patients to the best possible immuno-oncology therapy. Dawn is in the early validation process for use in patients with pancreatic and lung cancers as well as melanoma. Its application on other tumor types is continuously being studied.